Sign in3 stories
Spero entered a sales agreement with Jefferies for up to $100 million in stock sales and terminated its prior arrangement with Cantor Fitzgerald, both effective August 28, 2026.
SEC filing
Spero says FDA approval of Utebzi, a $105 million royalty financing, and an exclusive license for SP001 extend its cash runway into the second half of 2029.
SEC filing
Spero Therapeutics gains global rights outside Greater China to SP001 (IBI355) for IgG4-related disease and other immune conditions, backed by a separate $105 million royalty financing.
SEC filing